COVID-19 molecular test performance measures

Developer:

Cross Reactivity:

Primer Target:

Primer Specificity:

Primer Number:

RNA Extraction:

Developer	Test	Date EUA authorized	Sample types	Authorized setting: CLIA to perform high complexity tests	Authorized setting: CLIA to perform moderate complexity tests	Authorized setting: CLIA Waiver	Time until test results (Hours)	Positive percent aggreement (95% CI)	Negative percent aggrement (95% CI)	Cross-reactivity with common respiratory pathogens (Specificity)	Primer target region	Primer specificity to SARS COV-2	Primer number of target regions	LOD: Minimum amount in a spiked sample that can be detected at least 95% of the time	RNA extraction efffciency check	More Information